News
Legal Analysis - Scrip Regulatory Affairs
Pharmaceutical companies using the centralised authorisation procedure in the EU may be entitled to a slightly longer supplementary certificate procedure term than they might think, says Mike Snodin
This article appeared in the October issue of Scrip Regulatory Affairs
View attachment: Download File
